<DOC>
	<DOCNO>NCT01386567</DOCNO>
	<brief_summary>The purpose study determine continue effect Androxal morning testosterone reproductive status men secondary hypogonadism complete protocol ZA-203 . Men allow choose Androxal ( enclomiphene citrate ) Testim ( topical testosterone ) beginning study . All men Androxal start 12.5 mg allow titrate 25 mg inadequate response exhibit low dose .</brief_summary>
	<brief_title>A One Year Open Label Study Treatment Hypogonadism ( Low Testosterone ) Men Who Have Completed ZA-203</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Successful completion ZA203 Ability understand provide write informed consent Agreement use condom , fertile female partner , another form contraception Agreement provide semen sample clinic Any condition , opinion Investigator , would make Subject unsuitable candidate enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>hypogonadism</keyword>
	<keyword>low testosterone</keyword>
	<keyword>low T</keyword>
</DOC>